HCA completes $33 billion leveraged buyout — then-largest LBO in history — with Frist family retaining stake and board nomination rights

HCA Inc.’s take-private leveraged buyout closed on November 17, 2006 — a $33 billion transaction (roughly $21 billion in cash plus assumption/repayment of $11.7 billion in existing debt) led by Bain Capital, Kohlberg Kravis Roberts (KKR), and Merrill Lynch Global Private Equity, together with company co-founder Dr. Thomas F. Frist Jr. and the Frist family, who retained an approximately 4.4% stake at closing. At the time it was the largest leveraged buyout in private-equity history. The deal was announced in July 2006 at $51/share for the shares being acquired. HCA returned to public markets on March 9-10, 2011 as HCA Holdings, Inc., pricing an IPO of 87,719,300 shares at $30.00/share and beginning trading on the NYSE under ticker HCA.

Corporate continuity, verified via SEC EDGAR (this is the load-bearing finding for the ratchet question). SEC filer CIK 0000860730 shows unbroken, continuous filing from 1994 through 2026 under a sequence of names: Columbia Healthcare Corp (through 1994) → Columbia/HCA Healthcare Corp (1994-2000) → HCA - The Healthcare Company (2000-2001) → HCA Inc./TN (2001-2010) → HCA Holdings, Inc. (2010-2017) → HCA Healthcare, Inc. (2017-present). The 2006 LBO and 2011 re-IPO are ownership-structure and listing-status changes, not entity discontinuities — there is no new CIK, no successor-entity filing break, and no bankruptcy or asset-sale severance between the settling entity of 2000/2003 and today’s HCA Healthcare, Inc. The company that pled guilty and paid $1.7 billion in fraud settlements (2000-2003) is the same continuous legal filer as the company operating today’s hospital network and health-data infrastructure — not a restructured successor shielded from that history.

The Frist connection, checked against 2026 governance records (not assumed from founding role). Dr. Thomas F. Frist Jr. co-founded HCA in 1968 with his father Thomas F. Frist Sr. and Jack C. Massey, and negotiated the 2006 buyout as a continuing owner. He does not sit on HCA’s board today. Per HCA’s 2026 proxy materials, two of his sons — Thomas F. Frist III (Board Chairman since 2019, director since 2006) and William R. Frist (director since 2009, classified as an “Investor Director”) — hold board seats, and the “Frist Entities” collectively own approximately 28% of HCA’s common stock (over 70 million shares) with contractual rights, from the 2006 stockholders’ agreement, to nominate two board members. Former US Senator William H. “Bill” Frist — Thomas Frist Jr.’s brother, i.e. a different person from director William R. Frist (Thomas Jr.’s son / Frist III’s brother) — holds no current governance or ownership role at HCA; he chairs The Nature Conservancy’s board and sits on other companies’ boards (Select Medical, Teladoc Health), not HCA’s. The recurring public confusion between “Bill Frist” (the Senator) and “William R. Frist” (the current HCA director) is a namesake collision, not evidence that the Senator has a present HCA role.

Accountability-posture finding. The December 2000 Corporate Integrity Agreement’s compliance obligations ran through approximately 2008-2009 and were not renewed; HHS OIG’s current published CIA list (339 agreements, active and closed) shows no HCA-related listing as of this research. No structural oversight mechanism from the fraud era remains in force. Combined with unbroken corporate continuity and continuing Frist-family board representation and ~28% ownership, this is a documented instance of the forgiveness-over-accountability ratchet: the sanctioned entity is the same entity now operating at scale (including, per the companion procurement ticket, as a data-platform counterparty), and the sanction’s only structural constraint (the CIA) expired on schedule roughly seventeen years before this writing with no successor mechanism.